Aducanumab Terminated Phase 3 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02477800221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT02484547221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease